Page 3 - Novo Nordisk

Novo Nordisk is Europe's most valuable firm after launching obesity drug

The company's share price closed up 0.7 per cent to DKK 1,311 ($190), giving the company a market capitalisation of $428 billion

Novo Nordisk under EU probe after reports of suicidal, self-harm thoughts

Another patient on Saxenda, Novo's earlier and less effective weight-loss drug that contains a different active ingredient, reported thoughts of self-injury, the agency said

Eli Lilly's 'triple G' anti-obesity drug leads to 24% weight loss in trial

The pharma company published the results of phase two of the clinical trial of Retatrutide, showing impressive weight loss and regulation of blood sugar levels in undertrials

Novo Nordisk to double India manufacturing, bring new drugs by 2025

Plans to bring new drugs by 2025 into the country, which is part of all its global clinical trials

HCL Tech to provide global service desk, on-site support to Novo

IT services company HCL Technologies on Monday said it has been selected to provide global service desk and on-site support to global healthcare company Novo Nordisk

Novo Nordisk appoints Vikrant Shrotriya as MD, Corp V-P for India business

He returns to India after 13 years with an overall career spanning over 20 years in the healthcare industry in India and internationally

Nordisk and Sanofi log double-digit revenue growth in insulin pens

Around 6.98 million insulin pens were sold; it was 6.97 mn in the year-before period

Resistant to strain

Novo Nordisk premium will survive drug wars